Precision Epigenomics offers the EPISEEK multi-cancer detection (MCD) test, which analyzes hypermethylated DNA loci from a blood draw to screen for over 60 cancer types. This liquid biopsy provides earlier detection capabilities compared to traditional imaging and is more accessible than invasive biopsies. The service is designed for at-risk individuals, health-conscious adults, and healthcare providers seeking advanced diagnostic tools.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer screening methods often involve multiple tests for different cancer types, potentially delaying diagnosis and increasing costs. Existing methods may also be invasive or lack the specificity needed for early detection. This can lead to late-stage diagnoses and reduced treatment options.
Solution
Precision Epigenomics offers the EPISEEK™ test, a multi-cancer detection liquid biopsy that analyzes DNA methylation patterns from a single blood draw to detect over 20 types of cancer, including early stages. The EPISEEK™ test identifies cancer signals by examining cancer-related DNA methylation patterns unique to tumors, enhancing accurate detection. By detecting cancer earlier than traditional methods, EPISEEK™ aims to improve diagnostic accuracy and facilitate timely intervention. The test results are typically available within 7-10 days, providing healthcare providers with actionable information for patient management. The company is also developing EPISEEK-MPE, a multi-cancer detection assay, in the analysis of pleural effusion fluid to detect cancer.
Target Audience
The primary target audience includes individuals aged 45 or older and those with an elevated risk of cancer, as well as healthcare providers seeking advanced diagnostic tools for early cancer detection.
Features
- Detects over 20 types of cancer from a single blood draw
- Analyzes specific cancer-related DNA methylation patterns
- Identifies cancer signals at early stages
- Provides results in 7-10 days
- Non-invasive liquid biopsy approach
- Developing EPISEEK-MPE for cancer detection in pleural effusion fluid